Comparing Aridis Pharmaceuticals (ARDS) & Its Peers
Aridis Pharmaceuticals (NASDAQ: ARDS) is one of 545 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Aridis Pharmaceuticals to similar companies based on the strength of its dividends, institutional ownership, earnings, analyst recommendations, profitability, valuation and risk.
Institutional & Insider Ownership
0.2% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 46.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.8% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of current ratings for Aridis Pharmaceuticals and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aridis Pharmaceuticals Competitors||4491||12890||27500||991||2.54|
Aridis Pharmaceuticals presently has a consensus price target of $30.60, suggesting a potential upside of 198.25%. As a group, “Pharmaceutical preparations” companies have a potential upside of 48.45%. Given Aridis Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Aridis Pharmaceuticals is more favorable than its peers.
This table compares Aridis Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aridis Pharmaceuticals Competitors||-1,776.01%||-105.48%||-28.48%|
Valuation & Earnings
This table compares Aridis Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aridis Pharmaceuticals||$2.76 million||-$22.10 million||-1.46|
|Aridis Pharmaceuticals Competitors||$2.17 billion||$230.56 million||-4.06|
Aridis Pharmaceuticals’ peers have higher revenue and earnings than Aridis Pharmaceuticals. Aridis Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Aridis Pharmaceuticals beats its peers on 7 of the 12 factors compared.
About Aridis Pharmaceuticals
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.